Novo Nordisk and the future of obesity drugs; Exit Q&A with AstraZeneca’s Mene Pangalos; Illumina’s bad week; Layoffs sweep biotech; and more

Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add Endpoints Weekly. New to Endpoints? Sign up here.

With pharma…
Click here to view original post

Advertisement — Advertise with Biotech Networks